Invention Grant
- Patent Title: Method of eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient using bi-specific antibodies
-
Application No.: US17133448Application Date: 2020-12-23
-
Publication No.: US11945866B2Publication Date: 2024-04-02
- Inventor: Vladislav Sandler
- Applicant: Hemogenyx Pharmaceuticals LLC
- Applicant Address: US NY Brooklyn
- Assignee: HEMOGENYX PHARMACEUTICALS LLC
- Current Assignee: HEMOGENYX PHARMACEUTICALS LLC
- Current Assignee Address: US NY Brooklyn
- Agency: McCarter & English, LLP
- Agent Beverly W. Lubit
- The original application number of the division: US16091139
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; A61K45/06 ; A61P43/00 ; A61K39/00
Abstract:
The described invention provides compositions containing bi-specific antibodies that bind to human tyrosine kinase receptor FLT3/FLK2 receptor protein and to CD3 receptor protein expressed on T-cells and use of the compositions containing the bispecific antibodies in the preparation of a medicament for eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient.
Public/Granted literature
Information query
